May 10, 2022 / 09:40PM GMT
Jason Matthew Gerberry - BofA Securities, Research Division - MD in US Equity Research
All right, everybody. Thanks for joining us for our next company presenter at the Bank of America Annual Healthcare Conference in Las Vegas. My name is Jason Gerberry, I'm one of the biotech analyst at BofA, and I'm pleased to be introducing our next company presenter, Vaxcyte. We've got Grant Pickering, CEO; and we've got Jim Wassil, COO, with us on stage. Gentlemen, both, thanks for joining us.
Grant E. Pickering - Vaxcyte, Inc. - Co-Founder, CEO & Director
Thank you for having us.
Jason Matthew Gerberry - BofA Securities, Research Division - MD in US Equity Research
So maybe, I don't know, Grant, if you want to set the stage at all for Vaxcyte. Who you guys are as a company. Set the stage in terms of pneumococcal vaccination as a marketplace. I don't think that it needs a lot of context. It's a very large market at $7 billion global revenue, and forecasted to go, I think, upwards of like $8 billion to $10 billion in the future
Vaxcyte Inc at Bank of America Healthcare Conference Transcript
May 11, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers